• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • COVID-19

    Africa's largest clinical trial for early stage COVID-19 drugs launches

    The trial is examining the combination of two drugs aimed at preventing early cases of COVID-19 from progressing into severe disease.

    By Sara Jerving // 27 April 2021
    Ciclesonide, which is used to treat asthma, is one of the drugs to be used in the ANTICOV clinical trial. Photo by: Shingo Tosha / AFLO

    Researchers are recruiting participants for Africa’s largest clinical trial for treatments for early-stage COVID-19. The trial will examine a drug combination aimed at treating patients with mild-to-moderate cases, hoping to prevent their progression into critical cases.

    “It has been more than a year since COVID-19 was declared a pandemic, and while we have vaccines registered for use, there are still very few treatment options — especially for the early stage when we could prevent severe progression, potentially reduce transmission, and maybe prevent the risk of developing post-COVID conditions,” said Dr. Nathalie Strub-Wourgaft, director of the COVID-19 response for the nonprofit research and development organization Drugs for Neglected Diseases initiative, which is coordinating the trial.

    The ANTICOV study includes a consortium of 26 African and global research and development organizations and will take place in 13 African countries. The trial will examine the combination of antiparasitic nitazoxanide and inhaled corticosteroid ciclesonide. These drugs — which are commercially available and affordable — could potentially interfere with the replication of the virus in the body and decrease inflammation in the upper respiratory tract.

    Preventing severe disease is important because of weak health systems in countries with limited resources, said Dr. Borna Nyaoke-Anoke, senior clinical manager at DNDi, and in charge of the ANTICOV trial in Nairobi.

    “We cannot compare our health capacity with that in Europe or America. What might be considered a small number of severe diseases in the global north might have devastating consequences in Africa,” she said. “We want to prevent that progression to severe disease so that we don’t overwhelm our health care facilities.”

    Participants have already been recruited in the Democratic Republic of Congo and Republic of Guinea, and the trial expects to enroll more participants from Burkina Faso, Cameroon, Côte d’Ivoire, Equatorial Guinea, Ethiopia, Ghana, Kenya, Mali, Mozambique, Sudan, and Uganda in the coming weeks.

    Because of global shortages and countries hoarding vaccines, African countries have only received limited numbers of doses. New virus variants also threaten the efficacy of vaccines, making treatment options a crucial area of research.

    For example, Kenya’s current vaccination plan expects to receive about 49 million doses, which will only cover 30% of the population by June 2023. Because of this, Kenya is not expected to reach the herd immunity threshold of 60 to 70% before 2023 under the current plan, Nyaoke-Anoke explained.

    “It paints a bleak picture of when the continent will achieve herd immunity,” she said. “There is a great need to ensure that before everyone has access to these vaccines, for those who do get sick, we are able to assist them in curing the disease or preventing its progression into a more severe disease.”

    Researchers will continue to recruit people for the trial over the next six to seven months. They hope to have results by the end of this year, or early next year. There will also be interim analysis, so if researchers find that the drug combination is not effective before then, new drugs might be introduced into the trial.

    “For any disease that we’ve seen like polio, and other viral infections that we are trying to eradicate, therapeutics will always be needed in combination with vaccines,” Nyaoke-Anoke said.

    More reading:

    ► Clinical trials of COVID-19 treatments aim to bridge income gaps

    ► African Union aims to scale up COVID-19 vaccine clinical trials

    • Global Health
    • Research
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Sara Jerving

      Sara Jervingsarajerving

      Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.

    Search for articles

    Related Stories

    Global healthUSAID funding cuts jeopardize breakthrough drugs and research

    USAID funding cuts jeopardize breakthrough drugs and research

    Global healthUganda receives first pediatric drug for schistosomiasis. What's next?

    Uganda receives first pediatric drug for schistosomiasis. What's next?

    Escape the Neglect: Produced in PartnershipThe new reality of R&D funding for neglected tropical diseases

    The new reality of R&D funding for neglected tropical diseases

    Escape the Neglect: Produced in PartnershipWhy drug donation programs are a lifeline for NTD elimination efforts

    Why drug donation programs are a lifeline for NTD elimination efforts

    Most Read

    • 1
      The power of diagnostics to improve mental health
    • 2
      Lasting nutrition and food security needs new funding — and new systems
    • 3
      Opinion: Urgent action is needed to close the mobile gender gap
    • 4
      Supporting community-driven solutions to address breast cancer
    • 5
      No health reform without better AI governance
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement